A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor
An Open-label Study of the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor
Sponsor: Sage Therapeutics
Terminated
Internal company decision
Other terminated trials from Sage Therapeutics
More terminations from Sage Therapeutics
Other Essential Tremor trials with similar outcome
This PHASE2/PHASE3 trial investigates Essential Tremor and is currently terminated or withdrawn. Sage Therapeutics leads this study, which shows 12 recorded versions since 2022 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2/PHASE3
-
Nov 2024 — Sep 2025 [monthly]
Terminated PHASE2/PHASE3
Status: Active Not Recruiting → Terminated
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2/PHASE3
Status: Recruiting → Active Not Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2_PHASE3
▶ Show 7 earlier versions
-
Oct 2023 — Jun 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Jul 2023 — Sep 2023 [monthly]
Recruiting PHASE2_PHASE3
-
May 2023 — Jul 2023 [monthly]
Recruiting PHASE2_PHASE3
Phase: PHASE2 → PHASE2_PHASE3
-
Jan 2023 — May 2023 [monthly]
Recruiting PHASE2
-
Sep 2022 — Jan 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Sage Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .